-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NG-350A in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NG-350A in Endometrial Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NG-350A in Endometrial Cancer Drug Details: NG-350a is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NG-350A in Uterine Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NG-350A in Uterine Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NG-350A in Uterine Cancer Drug Details: NG-350a is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NG-350A in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NG-350A in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NG-350A in Triple-Negative Breast Cancer (TNBC) Drug Details: NG-350a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NG-350A in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NG-350A in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NG-350A in Esophageal Cancer Drug Details: NG-350a is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tazarotene in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tazarotene in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tazarotene in Idiopathic Pulmonary Fibrosis Drug Details: GRI-0621 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PBFT-02 in Frontotemporal Dementia (FTD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PBFT-02 in Frontotemporal Dementia (FTD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PBFT-02 in Frontotemporal Dementia (FTD) Drug Details: PBFT-02 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XH-001 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XH-001 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XH-001 in Solid Tumor Drug Details: XH-001 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KSD-101 in Hematological Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KSD-101 in Hematological Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KSD-101 in Hematological Tumor Drug Details: KSD-101 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MHB-088C in Esophageal Squamous Cell Carcinoma (ESCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Esophageal Squamous Cell Carcinoma (ESCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MHB-088C in Esophageal Squamous Cell Carcinoma (ESCC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAA-Specific CTLs in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAA-Specific CTLs in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAA-Specific CTLs in Solid Tumor Drug Details: Tumor Associated Antigen...